The shares of Moderna are up by over 8% today after the company revealed a single-shot vaccine booster for Covid and flu.
Moderna develops a single-shot vaccine for Flu and Coronavirus
Moderna has been one of the best-performing companies in recent months. The company’s stock price soared higher today after it announced the single-shot vaccine booster for Covid and flu. The shot is expected to make things much easier for people.
The new vaccine, which Moderna calls mRNA-1073, combines the company’s current Covid vaccine with a flu shot that is currently being developed. CEO Stephane Bancel stated that “Today, we are announcing the first step in our novel respiratory vaccine program with the development of a single-dose vaccine that combines a booster against COVID-19 and a booster against flu.”
She added that Moderna is making progress on enrolling patients into their rare disease programs. Furthermore, the company is fully enrolled in its personalized cancer vaccine trial. The CEO said they believe this is the start of a new age of information-based medicines.
Moderna has been one of the leading companies in terms of Covid vaccine. The company recently launched its mRNA-based two-dose Covid vaccine after gaining approval from the Food and Drug Administration last year. So far, nearly 150 million Moderna shots have been administered in the United States.
Moderna’s Stock Price Is Up By More Than 8%
The shares of Moderna have been rallying since the company announced the launch of its single-shot vaccine booster for Covid and flu. MRNA is up by 8% so far today, making it one of the best-performing stocks in the market.
MRNA is currently trading at $456 per share after its latest rally. Year-to-date, MRNA is one of the best-performing stocks in the market. It started in 2021 trading at $111 per coin, but it is now up by more than 300% since then.